Producing Proteins Using Transgenic Oilbody-Oleosin Technology - Progress has been significant in producing therapeutic proteins in plants. Insulin is an early candidate for commercialization. - BioPh

ADVERTISEMENT

Producing Proteins Using Transgenic Oilbody-Oleosin Technology
Progress has been significant in producing therapeutic proteins in plants. Insulin is an early candidate for commercialization.


BioPharm International
Volume 19, Issue 6


Quick Recap
OBi Des-B30 insulin was shown to function in a statistically identical manner (p < 0.05) to Humulin R pharmaceutical-grade and Roche research-grade insulin following intraperitoneal injection over the time-course of the study. All insulins tested significantly reduced plasma glucose levels (p < 0.05) in comparison to saline and a negative control fraction from Trypsin-cleaved wild-type Arabidopsis oilbodies. No toxic side effects were observed with OBi insulin. We are currently optimizing insulin expression in safflower and anticipate completing development of our production variety in 2006. SemBioSys is focusing its development efforts on those protein candidates where our platform addresses major commercialization challenges with respect to scale and cost of production, such as is the case with insulin.

Nancy Markley, Ph.D. is director of business development at SemBioSys Genetics Inc. , 110, 2985–23 Avenue, N.E. Calgary, Alberta, Canada T1Y 7L3, 403.717.8774, fax 403.250.3886,

Cory Nykiforuk, Ph.D. is biochemistry group leader at SemBioSys Genetics Inc.

Joe Boothe, Ph.D. is director of biochemistry at SemBioSys Genetics Inc.

Maurice Moloney, Ph.D. is founder and chief scientific officer at SemBioSys Genetics Inc.

REFERENCES

1. Werner RG. Economic aspects of commercial manufacture of biopharmaceuticals. J. Biotech. 2004; 113:171–182.

2. Roth GY. Bio-outsourcing report. Will bio-generics create a new CMO business? Contract Pharma 2004 June:43-50.

3. Ingley A, Pavlik J, Smith T. Transgenic protein production as an alternative manufacturing technology for pharmaceutical companies. Kellogg School of Management. Evanston IL. 2002; 1–28.

4. Boothe J and Markley NA. The design and use of transgenic plant expression systems for the production of foreign proteins. Recent Advances in Phytochemistry 2003:31–57.

5. World Health Organization, Diabetes mellitus. Fact Sheet N 138. 2002 April.

6. Datamonitor. Recombinant therapeutic proteins. 2004; Reference Code DMHC1975.

7. Nykiforuk CL, Boothe JB, Murray EW, Keon RG, Goren J, Markley NA, Moloney MM. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotechn. J. 2005; 3:77–85.

8. Kjeldsen T, Balschmidt P, Diers I, Hach M, Kaarsholm NC, and Ludvigsen S. Expression of insulin in yeast: The importance of molecular adaptation for secretion and conversion. Biotech. and Gen. Eng. Rev. 2001; 18:89–121.

9. Arakawa Y, Yu J, Chong DKX, Hough J, Engen PC, and Langridge WHR. A plant-based cholera toxin B subunit-insulin fusion protein protects against the development of autoimmune diabetes. Nature Biotech. 1998; 16:934–938.

ACKNOWLEDGEMENTS

We thank Liz Murray, Ph.D., Harm Deckers, Ph.D., Tara Girvitz, and Phillip Stephan for their contributions to the generation of data, preparation of figures and text, and critical review.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here